ArticleFrontiers in pediatrics2020

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.

Filiz Cicek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.